市售细胞性同种异体骨在脊柱融合中细胞作用检查:一项体内动物研究
研究采用无胸腺大鼠单节段后外侧腰椎融合模型,比较含颗粒状脱钙骨基质的细胞性骨基质、含纤维状脱钙骨基质的细胞性骨基质(活细胞与灭活状态)及无细胞纤维状脱钙骨基质共5组的融合效果;结果显示两种市售细胞性骨基质的细胞成分对脊柱融合无额外获益,纤维状脱钙骨基质组融合结果显著优于颗粒状脱钙骨基质组,脱钙骨基质成分可能是融合的关键决定因素。
要点
- 活细胞与灭活状态在同一细胞性骨基质组内的融合率、骨体积分数、μ-CT成熟度及组织学特征相当
- 纤维状脱钙骨基质组μ-CT成熟度评分为2.78±0.55,显著高于其他各组(p<0.0001)
- 作者认为脱钙骨基质成分而非细胞是脊柱融合的关键决定因素,并强调需设计良好的细胞性植骨材料临床研究
核心结论
- 两种市售细胞性骨基质的细胞成分在脊柱融合方面未带来额外获益。
- 含纤维状脱钙骨基质的组别融合结果显著优于含颗粒状脱钙骨基质的细胞性骨基质组,提示脱钙骨基质成分可能是融合的关键决定因素。
- 作者强调需要对细胞性植骨材料开展设计良好的临床研究。
研究设计与样本
- 研究检测3种市售植骨材料:含颗粒状脱钙骨基质的细胞性骨基质、含纤维状脱钙骨基质的细胞性骨基质、仅含纤维状脱钙骨基质的无细胞产品。
- 细胞性骨基质分别以活细胞状态(CBM-particulatev、CBM-fiberv)和灭活(冻干)状态(CBM-particulated、CBM-fiberd)使用,共5组。
- 在45只无胸腺大鼠上行单节段后外侧腰椎融合,每种产品3个批次植入,每组9只动物。
- 植骨材料内活细胞计数及骨形态发生蛋白-2含量采用酶联免疫吸附试验测定。
- 术后6周采用手法触诊、显微计算机断层扫描和组织学分析评估融合。
主要发现
- 含活细胞的2组细胞计数相当,两两比较显示5组间骨形态发生蛋白-2含量无显著差异。
- 手法触诊显示融合率:DBM-fiber组9/9、CBM-fiberd组9/9、CBM-fiberv组8/9、两个CBM-particulate组均为0/9。
- μ-CT成熟度评分在DBM-fiber组为2.78±0.55,显著高于其他各组(p<0.0001);定性评估中CBM-particulate样本均未见横突间融合。
- 各细胞性骨基质组内活细胞与灭活样本在融合率、骨体积分数、μ-CT成熟度评分及组织学特征方面相当。
临床怎么用
- 作者认为细胞在脊柱融合中未带来额外获益,并强调需要对细胞性植骨材料开展设计良好的临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the extensive use of cellular bone matrices (CBMs) in spine surgery, there is little evidence to support the contribution of cells within CBMs to bone formation. The objective of this study was to determine the contribution of cells to spinal fusion by direct comparisons among viable CBMs, devitalized CBMs, and cell-free demineralized bone matrix (DBM). METHODS: Three commercially available grafts were tested: a CBM containing particulate DBM (CBM-particulate), a CBM containing DBM fibers (CBM-fiber), and a cell-free product with DBM fibers only (DBM-fiber). CBMs were used in viable states (CBM-particulatev and CBM-fiberv) and devitalized (lyophilized) states (CBM-particulated and CBM-fiberd), resulting in 5 groups. Viable cell counts and bone morphogenetic protein-2 (BMP-2) content on enzyme-linked immunosorbent assay (ELISA) within each graft material were measured. A single-level posterolateral lumbar fusion was performed on 45 athymic rats with 3 lots of each product implanted into 9 animals per group. After 6 weeks, fusion was assessed using manual palpation, micro-computed tomography (μ-CT), and histological analysis. RESULTS: The 2 groups with viable cells were comparable with respect to cell counts, and pairwise comparisons showed no significant differences in BMP-2 content across the 5 groups. Manual palpation demonstrated fusion rates of 9 of 9 in the DBM-fiber specimens, 9 of 9 in the CBM-fiberd specimens, 8 of 9 in the CBM-fiberv specimens, and 0 of 9 in both CBM-particulate groups. The μ-CT maturity grade was significantly higher in the DBM-fiber group (2.78 ± 0.55) compared with the other groups (p < 0.0001), while none of the CBM-particulate samples demonstrated intertransverse fusion in qualitative assessments. The viable and devitalized samples in each CBM group were comparable with regard to fusion rates, bone volume fraction, μ-CT maturity grade, and histological features. CONCLUSIONS: The cellular component of 2 commercially available CBMs yielded no additional benefits in terms of spinal fusion. Meanwhile, the groups with a fiber-based DBM demonstrated significantly higher fusion outcomes compared with the CBM groups with particulate DBM, indicating that the DBM component is probably the key determinant of fusion. CLINICAL RELEVANCE: Data from the current study demonstrate that cells yielded no additional benefit in spinal fusion and emphasize the need for well-designed clinical studies on cellular graft materials.
引用
- Abedi A, Formanek B, Russell N, et al. Examination of the Role of Cells in Commercially Available Cellular Allografts in Spine Fusion: An in Vivo Animal Study. J Bone Joint Surg Am. 2020. PMID: 33079897. doi:10.2106/JBJS.20.00330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。